Advertisement
ABVX vs IMNN
Which Stock Would AI Choose? Abivax Société Anonyme (ABVX) vs. Imunon, Inc. (IMNN) Stock Comparison
Key Takeaways
- Abivax Société Anonyme (ABVX) operates as a clinical-stage biotechnology company targeting chronic inflammatory diseases, while Imunon, Inc. (IMNN) focuses on DNA-based immunotherapies primarily for ovarian cancer.
- ABVX shares have delivered exceptional long-term gains exceeding 2,000% over the past year amid clinical progress, trading near $122 with a market capitalization around $9.7 billion.
- IMNN shares trade near $2.20 with a market capitalization of approximately $9 million, showing positive year-to-date returns around 42% but significant volatility and recent monthly declines following earnings results.
- Both companies remain pre-revenue clinical-stage entities exposed to binary trial outcomes, regulatory hurdles, and dilution risks typical of the biotechnology sector.
- Recent market activity indicates ABVX benefiting from sustained momentum and analyst attention, whereas IMNN faces pressure from cash burn and mixed clinical updates.
- Relative performance highlights ABVX's larger scale and visibility versus IMNN's narrower focus and higher sensitivity to near-term financing needs.
Introduction
Abivax Société Anonyme (ABVX) and Imunon, Inc. (IMNN) represent two distinct clinical-stage biotechnology companies navigating the high-risk, high-reward environment of drug development. This comparison examines their business models, recent stock behavior, and relative positioning in the current market. Institutional investors, momentum traders, and sector specialists monitoring small- and mid-cap biotechs often review such pairings to assess diversification opportunities or tactical allocations within healthcare portfolios.
ABVX Overview and Recent Performance
Abivax Société Anonyme (ABVX) develops therapies that modulate immune responses for chronic inflammatory conditions and certain viral infections. The company maintains a clinical pipeline centered on its lead candidate for ulcerative colitis and related indications. In recent market activity, ABVX shares have exhibited strong upward trajectory over the past year, with gains exceeding 2,000% from depressed levels, supported by positive clinical data readouts and increased analyst coverage. Trading volume has remained elevated, reflecting broad investor interest. Recent weeks have shown continued resilience despite broader sector fluctuations, with the stock holding near the upper end of its 52-week range.
IMNN Overview and Recent Performance
Imunon, Inc. (IMNN) advances DNA-based immunotherapies and vaccines, with its lead program IMNN-001 in Phase 3 development for advanced ovarian cancer. The company also explores applications in other solid tumors and infectious diseases through its proprietary platforms. In recent market activity, IMNN shares have posted year-to-date gains near 42%, though they have experienced notable pressure over the past month amid quarterly results and ongoing cash requirements. The stock trades at low absolute levels with modest average daily volume, consistent with its micro-cap profile and sensitivity to clinical milestones or financing announcements.
Trending AI Robots
Tickeron maintains a curated Trending AI Robots page that showcases select AI trading bots from a library of hundreds capable of trading thousands of tickers. Only those demonstrating the strongest alignment with prevailing market conditions, including trend consistency and risk-adjusted metrics, earn placement in this section. Available bots span diverse trading styles, strategies, timeframes, and performance statistics, allowing users to review ranges such as varying win rates, drawdown profiles, and holding periods. This selection process highlights bots suited to current volatility and sector rotation patterns. For additional details, visit the Trending AI Robots page.
Head-to-Head Comparison
Abivax Société Anonyme (ABVX) and Imunon, Inc. (IMNN) differ markedly in scale, pipeline focus, and market presence. ABVX targets broader inflammatory disease markets with a more advanced corporate profile and substantially higher market capitalization, while IMNN concentrates on oncology-specific DNA immunotherapies with a narrower therapeutic window. Recent momentum favors ABVX, which has sustained longer-term appreciation and greater liquidity, whereas IMNN shows shorter-term year-to-date gains offset by higher volatility and lower trading volume. Sector exposure remains similar within biotechnology, yet ABVX benefits from wider analyst following and potential partnership interest, introducing trade-offs around execution risk and capital access for IMNN.
Tickeron AI Verdict
Based on observable factors such as trend consistency over recent weeks, relative stability in price action, and positioning around clinical catalysts, Tickeron’s AI models would currently assign a higher probabilistic preference to Abivax Société Anonyme (ABVX). This assessment reflects ABVX’s stronger momentum profile and larger operational footprint compared with IMNN’s more constrained liquidity and recent performance pressures. Outcomes remain subject to ongoing clinical and market developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABVX is a Buy and IMNN is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IMNN’s FA Score shows that 0 FA rating(s) are green whileABVX’s FA Score has 0 green FA rating(s).
- IMNN’s FA Score: 0 green, 5 red.
- ABVX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABVX’s TA Score shows that 5 TA indicator(s) are bullish while IMNN’s TA Score has 2 bullish TA indicator(s).
- ABVX’s TA Score: 5 bullish, 5 bearish.
- IMNN’s TA Score: 2 bullish, 3 bearish.
Price Growth
ABVX (@Biotechnology) experienced а -7.63% price change this week, while IMNN (@Biotechnology) price change was -6.99% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +3.42%. For the same industry, the average monthly price growth was +1.98%, and the average quarterly price growth was +1906.15%.
Reported Earning Dates
ABVX is expected to report earnings on Sep 21, 2026.
IMNN is expected to report earnings on Aug 06, 2026.
Industries' Descriptions
@Biotechnology (+3.42% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ABVX | IMNN | ABVX / IMNN | |
| Capitalization | 7.81B | 7.27M | 107,387% |
| EBITDA | -298.47M | -14.14M | 2,110% |
| Gain YTD | -31.400 | -54.593 | 58% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 0 | 0 | - |
| Total Cash | 492M | 4.79M | 10,263% |
| Total Debt | 1.45M | 912K | 159% |
IMNN | ||
|---|---|---|
OUTLOOK RATING 1..100 | 56 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 40 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 90 | |
P/E GROWTH RATING 1..100 | 100 | |
SEASONALITY SCORE 1..100 | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| ABVX | IMNN | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 82% | 1 day ago 78% |
| Stochastic ODDS (%) | 1 day ago 78% | 1 day ago 76% |
| Momentum ODDS (%) | 1 day ago 74% | N/A |
| MACD ODDS (%) | 1 day ago 88% | 1 day ago 88% |
| TrendWeek ODDS (%) | 1 day ago 80% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 89% | 1 day ago 90% |
| Advances ODDS (%) | 21 days ago 87% | N/A |
| Declines ODDS (%) | 1 day ago 80% | 1 day ago 90% |
| BollingerBands ODDS (%) | 1 day ago 71% | N/A |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 90% |
Advertisement
ABVX and Stocks
Correlation & Price change
A.I.dvisor indicates that over the last year, ABVX has been loosely correlated with IMNN. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ABVX jumps, then IMNN could also see price increases.
| Ticker / NAME | Correlation To ABVX | 1D Price Change % | ||
|---|---|---|---|---|
| ABVX | 100% | -6.01% | ||
| IMNN - ABVX | 58% Loosely correlated | -2.81% | ||
| XENE - ABVX | 38% Loosely correlated | +1.79% | ||
| DYN - ABVX | 37% Loosely correlated | +0.35% | ||
| ZYME - ABVX | 36% Loosely correlated | +1.80% | ||
| IRON - ABVX | 35% Loosely correlated | -0.11% | ||
More | ||||
IMNN and Stocks
Correlation & Price change
A.I.dvisor indicates that over the last year, IMNN has been loosely correlated with ABVX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if IMNN jumps, then ABVX could also see price increases.
| Ticker / NAME | Correlation To IMNN | 1D Price Change % | ||
|---|---|---|---|---|
| IMNN | 100% | -2.81% | ||
| ABVX - IMNN | 58% Loosely correlated | -6.01% | ||
| REPL - IMNN | 57% Loosely correlated | -1.31% | ||
| STOK - IMNN | 30% Poorly correlated | -2.31% | ||
| DNLI - IMNN | 30% Poorly correlated | +0.32% | ||
| DTIL - IMNN | 29% Poorly correlated | -3.02% | ||
More | ||||